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Background and Methods: Steroid-refractory acute GVHD (SR-
GVHD) remains a significant complication of allogeneic hematopoi-
etic cell transplantation (HCT). Prochymal (Mesenchymal Stem
Cells, MSC, derived from unrelated volunteer adult donors) was
evaluated in addition to standard of care, including institutionally se-
lected second line treatment, in a randomized (2:1) trial in patients
with SR-GVHD (Protocol 280). Patients received 8 infusions of 2
 106 MSC/kg over 4 weeks (or volume equivalent for placebo),
with an additional 4 infusions administered weekly after day 28 in pa-
tients who had a partial response, defined as improvement in at least
one organ without progression in others. The primary endpoint was
durable complete response (DCR) for$ 28 days. Additional pro-
spectively defined outcomes included responses in patients by organ
involvement. P-values were based on Chi-square tests, unless other-
wise specified.
Patients and Results: 244 patients with SR-GVHD (skin involve-
ment n5 144, GI involvement n5 179, liver involvement n5 61)
were enrolled and treated on study: Prochymal (n5 163), placebo
(n5 81). There were no significant differences in age, pre-trans-
plant conditioning, graft source, HLA-matching or second-line
therapy between treatment arms. For the Prochymal and placebo
arms, respectively, the grades of GVHD at entry were B (22%
vs. 26%), C (51% vs. 58%), and D (27% vs. 16%). The respective
DCR rates were 35% vs. 30% (p5 0.3) in the ITT population and
40% vs. 28% (p5 0.08) in the per protocol population. Results for
secondary endpoints are shown in the table. Patients with GvHD
affecting all 3 organs had overall complete or partial responses
rate of 63% vs. 0% (n5 22, p\0.05, Fisher’s exact test) at day
28. Patients treated with Prochymal had less progression of liver
GVHD at weeks 2 and 4 respectively (32% vs 59%, p5 0.05;
and 37% vs. 65%, p5 0.05). The incidence of infections was not
different between arms. Incidence rates were 9% vs. 8% for recur-
rent malignancy, 1.8% vs. 2.5% for infusional toxicity, and 0.6%
vs. 4.6% for discontinuation due to an AE in Prochymal versus
Placebo, respectively.
Conclusion:GVHDwith liver or gut involvement is a life-threaten-
ing complication of HCT. Our results suggest that the addition of
Prochymal produced significant improvement without additive tox-
icity in patients with SR-GVHD involving visceral organs.
Overall Complete or Partial Response Rates in Patients
According to Organ Involvement
Day 100 Response RateOrgan Prochymal Placebo Odds Ratio 95% CI P ValueOverall 82% 73% 1.7 0.9-3.1 0.12
Skin 78% 77% 1.1 0.5-2.4 0.9
Liver 76% 47% 3.6 1.1-11.2 \0.05
Gut 82% 68% 2.2 1.1-4.4 \0.0542
CRUCIAL ROLE FOR CROSS-PRESENTATION IN THE INDUCTION OF GVHD
BY T CELLS DIRECTED AGAINST A SINGLE IMMUNODOMINANT MINOR
HISTOCOMPATIBILITY ANTIGEN DESPITE LACK OF EPITOPE SPREADING
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The current paradigm indicates that epitope speading is critical
for GVHD after MHCmatched minor antigen (miHA) mismatched
BMT. Because clinical data suggest that sex mismatched antigens are
relevant miHAs for GVH responses, we directly tested relevance of
epitope spreading by inducingGVHDin the presence of only a single
immuno-dominant Y antigen disparity. We utilized female (F)/
male(M) MHC matched BMT with anti-H-Y monospecific,
H-2(b)-restricted T cell receptor transgenic (TCR Tg) MataHariCD8+ T cells. B6 [M and F] animals were lethally irradiated and
transplanted with TCD BM and 1106 splenic CD8+ T cells from
\MataHari donors. None of the syngeneic female B6 animals devel-
oped GVHD and all of them survived. By contrast, all of the alloge-
neic male animals that received MataHari T cells showed severe
clinical GVHD and died after BMT (P\0.0001, see Table).
GVHD specific death was confirmed by target organ (GI tract and
liver) histopathology on day +7 after BMT (P\0.005). To deter-
mine if the precursor frequency alloreactive donor T cells is critical,
we reduced the dose of the MataHari T cells by ten fold (1105) and
mixed them with syngeneic T cells (1:9 ratio) from male B6 donors.
Significant GVHD mortality was observed in the MataHari group
(33% vs. 0%, P\0.01) demonstrating that the presence of sufficient
precursor T cells against a single immuno-dominat miHA can
induce significant GVHD even in the absence of epitope spreading.
GVHD mortality was also observed when two other anti-H-Y spe-
cific TCR Tg CD4+ (Marilyn and Rachel) were utilized as donor
T cells ruling out any CD8+ T cell only or strain dependent artifacts.
Mechanistic studies were performed to determine whether direct
and/or cross-presentation (on host or donor hematopoietic derived
APCs) of the immunodominant miHA is critical for GVHD.
[F/M], [II-/-/M] and [M/ F] bone marrow chimeras gener-
ated, lethally re-irradiated and injected with TCD-BM and Marilyn
CD4+ T cells. The [F/M], [II-/-/M] animals (express HY anti-
gen on only non-hematopoietic target cells) died from severe
GVHD while the [M/ F] animals (express HY antigen on only
hematopoietic cells) showed only modest GVHD. Collectively our
data (see Table) demonstrate that (a) in contrast to the current
dogma, epitope spreading is not always required for GVHD (b)
the immunodominant antigen expression on target tissues is critical
and (c) this antigen can be efficiently cross-presented by either host
or donor APCs.
GVHD across single immuno-dominant Yantigen miHA
GVHD mortality
Donor T cells (all of B6\ TCDBM) Recipient * P\0.01MataHari (CD81 Tg, 1x106) B6 (female) 0%
MataHari (CD81 Tg, 1x106) B6 (male) 100%
MataHari (CD81 Tg, 0.1x106) B6 (male) 33%
Marilyn (CD41 Tg, 1x106) B6 (male) 100%
Rachel (CD41 Tg, 1x106) B6 (male) 100%
Marilyn (CD41 Tg, 1x106) [B6\ into B6_ 100%
Marilyn (CD41 Tg, 1x106) [B6(male) into B6\ 25%
Marilyn (CD41 Tg, 1x106) [II-/- into B6_ 100%43
PROSPECTIVE EVALUATION OF PROTEOMIC PATTERN SPECIFIC FOR
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Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is a curative treatment for many hematologic malignancies or hema-
topoietic dysfunction syndromes in adult patients, but the applica-
tion is still limited due to major complications, such as severe graft
versus host disease (GvHD) and/or infectious complications. Diag-
nosis of aGvHD is based on clinical features and biopsies, a non
invasive, unbiased laboratory test was developed earlier and has
been evaluated prospectively and blinded onmore than 1290 samples
collected from more than 327 patients undergoing allo-HSCT at
Hannover Medical School (MHH) and 7 additional clinics. The
majority of the patients included was transplanted for hematological
malignancies (n5 320), 9 for hematopoietic failure syndromes,
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reduced intensity conditioning regimens (RIC) for about 60% of
the patients of MHH, as well as standard conditioning regimens
(mainly TBI + Cy or Busulfan + Cy). GvHD-prophylaxis was cyclo-
sporine A (CSA) and mycophenolate (MMF) or CSA metothrexate
(MTX), as appropriate. In addition, about 80% percent of the pa-
tients received ATG (antithymocyte globulin) prior to HSCT.
A peptide pattern of 31 peptides – either absent/decreased (15) or
present/increased (16) – was previously published (Weissinger et al.
2007), a new pattern MS_17 was developed and prospectively evalu-
ated in parallel for the last 2 years. Prospective and blinded evalua-
tion of the patients included in this analysis for early recognition
of patients at risk for aGvHD development revealed the correct clas-
sification of patients developing aGvHD about 7 days prior to the
development of clinical symptoms for aGVHD with a sensitivity
76% and specificity of about 85%. Additional data on the efficacy
of a pilot study for pre-emptive therapy driven by pattern positivity
yielded encouraging results on incidence and severity of aGvHDwill
be reported. Based on these data a pre-emptive therapy multicenter
trial, administering steroids upon positivity of the proteomic pattern
has been initiated now in 10 German centers, testing the efficacy of
the pre-emptive therapy on incidence and severity of aGvHD and
a possible benefit on overall survival of the patients.44
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Chronic graft versus host disease (GvHD), or late acute GvHD
play a major role in morbidity, but also mortality of patients post al-
logeneic HSCT. Diagnosis chronic GvHD is based on clinical fea-
tures and biopsies, a non invasive, unbiased laboratory test does
not exist.
We established a proteomic screening test for cGvHD by using
capillary electrophoresis (CE) coupled on line to an ESI-Tof (elec-
trospray-ionization time of flight) mass spectrometer (MS). Screen-
ing urine collected from 20 patients (10 with limited cGvHD, 10
with extensive cGvHD) we established a proteomic pattern allowing
the diagnosis of cGvHD development. The resulting set of polypep-
tide markers (27 differentially excreted peptides) was tested on more
than 227 patients prospectively and blinded for the correct classifica-
tion of cGvHD samples. The majority of the patients included were
transplanted for hematological malignancies (n5 209), 6 for hema-
topoietic failure syndromes. The cGvHD proteomic pattern of 27
peptides was established by using 20 cases and 20 controls, consisting
of patients at least 100 days post-HSCT, with no GvHD in the his-
tory, no infections andwithout relapse at the time of sampling. Apro-
teomic pattern differentiating chronic from acute GvHD was
developed, since the initial pattern did cross react with aGvHD pa-
tients.Prospective and blinded evaluation of the patients revealed
the correct classification of patients developing cGvHD with a
sensitivity of 85% and specificity of 95%. Interestingly, urine from
patients developing GvHD post DLI did react with the cGvHD-
pattern and is predictive for GvHD developing post-DLI (about 2
weeks prior toDLI-GvHDdevelopmentWhen the aGvHD-specific
proteomic pattern was applied to the screening of patients with DLI
in order to predict GvHD, only GvHD of the intestine reacted sig-
nificantly with the aGvHD pattern. Further evaluations of the
cGvHDpatterns specific for particular organ manifestations are cur-
rently ongoing.45
GRAFT-VERSUS-LEUKEMIA ANTIGEN CML66 ELICITS COORDINATED B
AND T CELL IMMUNITY AFTER DONOR LYMPHOCYTE INFUSION
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Sasada, T., Ritz, J., Wu, C.J. Dana-Farber Cancer Institute, Boston, MA
Donor lymphocyte infusion (DLI) is a highly effective treatment
for relapsed chronicmyeloid leukemia (CML) after allogeneic hema-
topoietic stem cell transplantation (HSCT), in which 70-80% pa-tients achieve curative responses. Despite its clinical efficacy, the
mechanism by which DLI achieves anti-tumor immunity remains
incompletely understood. CML66 is a CML-associated antigen
that is preferentially expressed in myeloid progenitor cells. CML66
elicited a potent antibody response in a patient with CML who
achieved complete molecular remission following CD4 +DLI in
the absence of graft-versus-host disease. Since CD4 + T cell re-
sponses often generate both antigen-specific antibody and CD8 + T
cell responses, we queried whether anti-CML66 antibodies were
associated with the development of cytolytic T cell immunity against
the same protein. CML66-reactive T cell clones were detected and
found to be directed against a naturally processed and presented
HLA-B*4403-restricted epitope (HDVDALLW). This T cell epi-
tope (at residues 459-467) is positioned in a different region of the
protein compared to the B cell epitope (at residues 198-217: GFYV-
SLEWVTISKKNQDNK).Neither antibodynorTcell responses to
CML66 were detectable in peripheral blood prior to DLI, by ELISA
or ELISpot assays, respectively. However, starting as early as one
month after DLI, CD8 +T cells and then high-titer plasma antibody
to CML66were readily detected in peripheral blood, in close tempo-
ral correlation with disease remission. Examination of marrow by
ELISpot 1 month after DLI revealed a 10 fold increased frequency
of CML66-reactive CD8 +T cells compared to peripheral blood.
TheCML66-reactiveT cell clone could be also detected at low levels
in vivo in patient marrow prior to DLI by ELISpot and nested PCR,
in associationwith progressive leukemic relapse, but not in peripheral
blood pre-DLI, nor in peripheral blood of the stem cell donor. These
results suggest that marrow is a reservoir of donor T cells primed
against patient leukemia following HSCT. Infusion of CD4+ donor
T cells appears to result in the rapid expansion of pre-existing mar-
row-resident leukemia-specific CD8 +T cells, followed by a cascade
of antigen-specific immune responses detectable in the periphery.
Our detailed analysis of this single antigen demonstrates that both
B and T cell immunity contribute to effective tumor immunity that
is directed at least in part to nonpolymorphic overexpressed leukemia
antigens.46
IN CML PATIENTS, RESIDUAL DISEASE IN PRIMITIVE STEM/PROGENITOR
CELLS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IS
HIGHER THAN AFTER TREATMENT WITH TYROSINE KINASE INHIBITORS
ALONE, BUT IS STILL AMENABLE TO GVL EFFECTS
Yong, A.S.M., Keyvanfar, K., Eniafe, R., Savani, B.N., Rezvani, K.,
Shenoy, A., Koklanaris, E.K., Musse, L., Donohue, T., Le, Q.,
Goldman, J.M., Barrett, A.J. National Heart, Lung and Blood Institute,
National Institutes of Health, Bethesda, MD
Although tyrosine kinase inhibitors (TKI) have replaced allogeneic
stem cell transplantation (SCT) as first-line therapy for chronic my-
eloid leukemia (CML), TKIs do not eradicate all CML cells. Simi-
larly, although SCT cures CML patients, minimal residual disease
(MRD) not fulfilling criteria for molecular relapse is also found
post-SCT.We compared the level of BCR-ABL transcripts in primi-
tive hematopoietic cells from patients who were treated with T-
depleted SCT with scheduled T-cell addback from D + 45 to
D + 100 post-SCT (n5 38) with levels in those taking TKIs
(n5 5). CD34+ cells were isolated from post-SCT leukaphereses at
D + 120 (n5 13), peripheral blood (PB) from D + 60 – 66 months
(n5 19), bone marrow aspirates from patients on long-term follow-
up (4-12 years) (n5 17), or 15 – 18months post-TKI treatment alone
(n5 5); serial post-SCT samples were available in 12 patients.Hema-
topoietic stem cells (HSC, CD34 + CD38-Lin-CD90+), common
myeloid progenitors (CMP, CD34 + CD38 + Lin- IL3Ra + C-
D45RA-) and granulocyte-macrophage progenitors (GMP,
CD34 + CD38 + Lin- IL3Ra + CD45RA+) were flow-sorted, and
BCR-ABL expressionmeasured using quantitative PCRwith the sen-
sitivity to detect one BCR-ABL-positive cell in 106 normal cells. Of
twenty patients with PB MRD-negativity (n5 19 post-SCT, n5 1
post-TKI), an 11-year post-SCT patient had detectable BCR-ABL
transcripts in CMPs, and subsequently fulfilled criteria for molecular
relapse. Among PB MRD-positive patients, 3/19 (16%) post-SCT
and 2/3 (67%) post-TKI did not have detectable BCR-ABL tran-
scripts in HSC, CMP or GMP populations. In 16/19 (84%) PB
MRD-positive post-SCT patients BCR-ABL transcripts were de-
tected in at least one CD34+ subpopulation, with the highest levels
